Trial	Phase	Sponsor	Dist.
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)	Phase 2	Zura Bio Inc	<1 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Phase 3	Novartis Pharmaceuticals	<1 mi
Study of COYA 302 for the Treatment of ALS	Phase 2	Coya Therapeutics	<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	<1 mi
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis	Phase 3	Sanofi	<1 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis	Phase 3	Sanofi	<1 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Phase 1/2	UniQure Biopharma B.V.	<1 mi
Multiple Sclerosis Implementation Network (Registry)	—	The University of Texas Health Science Center, Houston	<1 mi
Non-invasive BCI-controlled Assistive Devices	N/A	University of Texas at Austin	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS	Phase 1	ProJenX	<1 mi
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years	Phase 2	ModernaTX, Inc.	<1 mi
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	Phase 2	Eli Lilly and Company	<1 mi
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis	Phase 3	Celgene	<1 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Phase 1	National Cancer Institute (NCI)	<1 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	<1 mi
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Phase 4	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS	N/A	The Methodist Hospital Research Institute	<1 mi
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis	Phase 1	Amylyx Pharmaceuticals Inc.	<1 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2	Darcy Krueger	<1 mi
Care in Multiple Sclerosis (MS)	—	NYU Langone Health	<1 mi
NARCOMS Registry: A Multiple Sclerosis Registry	—	University of Texas Southwestern Medical Center	<1 mi
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease	—	TScan Therapeutics, Inc.	7 mi
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation	N/A	The University of Texas at Dallas	13 mi
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)	Phase 3	Amgen	26 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.